Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Shire Limited’s Elaprase given backing

Shire Limited’s Elaprase given backing

27th May 2008

A new enzyme replacement therapy has been given approval as an effective treatment for Hunter syndrome.

Shire Limited’s Elaprase therapy was backed by the Agencia Nacional de Vigilancia Sanitaria and now becomes the first of its type to be given the go-ahead for use in curing the disease.

Commenting on the announcement, Professor Roberto Giugliani of the Hospital de Clínicas de Porto Alegre said that the availability of Elaprase will mean more physicians will be able to get their patients beyond the palliative care phase.

“This is a tremendous milestone for the many Hunter syndrome patients in Brazil, who will now have access to treatment for this serious and life-threatening disease,” he said.

Hunter syndrome is also known as Mucopolysaccharidosis II – or MPS II – and can be particularly fatal in children, with symptoms including bone deformities typically appearing by the age of two or three years old.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.